<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00705549</url>
  </required_header>
  <id_info>
    <org_study_id>CT/07.23</org_study_id>
    <nct_id>NCT00705549</nct_id>
  </id_info>
  <brief_title>Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer</brief_title>
  <official_title>Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Crete</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective pilot phase II trial, in patients with wet stage IIIb and IV NSCLC
      using chemotherapy regimens which will be defined according to the pharmacogenomic profile
      (tumoral expression of ERCC1, BRCA1 and RRM1) of the tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Advanced stage NSCLC is essentially a fatal disease and treatment is mainly palliative.
      Systemic cisplatin-based chemotherapy remains the mainstream for the treatment of advanced
      non-small cell lung cancer (NSCLC) since it improves survival, symptom control and quality of
      life compared to best supportive care.

      The selection of appropriate treatment for individual patients remains a challenge in
      clinical oncology, particularly in the advanced disease. Several lines of evidence indicate
      that polymorphisms, gene transcripts and gene mutations can play a predictive role and can be
      used to tailor chemotherapy in different subgroups of cancer patients. There are evidence
      lead us to use the expression levels of ERCC1 by the tumor as a molecular marker for
      customized chemotherapy. Another gene, the BRCA1 has a crucial role in DNA repair, since it
      is implicated in transcription-coupled nucleotide excision repair (TC-NER), leading to radio-
      and chemo-resistance. RRM1,localized in 11p15.5,also acts as a putative tumor suppressor
      gene. RRM1 overexpression was related to gemcitabine resistance in human oropharyngeal
      epidermoid carcinoma KB cells as well as in patients with NSCLC. For those reason we decided
      to conduct a prospective pilot phase II trial, in patients with wet stage IIIb and IV NSCLC
      using chemotherapy regimens which will be defined according to the pharmacogenomic profile
      (tumoral expression of ERCC1, BRCA1 and RRM1) of the tumor cells.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to poor accrual
  </why_stopped>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) based on the pharmacogenomic profile of the ERCC1, RRM1 and BRCA1 expression</measure>
    <time_frame>Objective responses confirmed by CT or MRI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence of the different pharmacogenomic profiles as defined by the combined expression of ERCC1, RRM1 and BCRA1</measure>
    <time_frame>Comparison of molecular determinants for response in the primary tumor and peripheral blood (ERCC1 polymorphism ,TXR1 and TSP1 mRNA expression by Q-RT-PCR, Molecular markers related to responsiveness to Alimta )</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Toxicity assessment on each chemotherapy cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Non-Small-Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemzar/Cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taxotere/Cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin/Navelbine metronomic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taxotere/Gemzar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemzar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taxotere</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Navelbine metronomic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alimta/Cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alimta/Gemzar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taxotere</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alimta</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>9</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin I.V at the dose of 75mg/m2 on Day 1</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>8</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel I.V at the dose of 75mg/m2 on Day 1</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>10</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin I.V at the dose of 80mg/m2 on Day 1</description>
    <arm_group_label>3</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinorelbine per os 50mg every Monday, Wednesday and Friday</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexate</intervention_name>
    <description>Pemetrexate I.V 500mg/m2 on Day 1</description>
    <arm_group_label>8</arm_group_label>
    <arm_group_label>9</arm_group_label>
    <arm_group_label>11</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven Stage IV and Stage III (with malignant pleural or
             pericardial effusion) squamous or adenocarcinoma carcinomas of the lung

          -  Adequate Formalin Fixed Paraffin Embedded tumor sample provided for molecular analysis

          -  No previous anticancer treatment for metastatic/advanced disease. Patients who
             received prior adjuvant chemotherapy are eligible if they have remained free of
             disease for at least 6 months after the completion of adjuvant therapy.

          -  Age above 18 years

          -  Performance status (ECOG) 0-2

          -  Life expectancy &gt;= 3 months

          -  Effective contraception for both male and female subjects if the risk of conception
             exists

          -  Adequate hematologic parameters (absolute neutrophil count &gt;= 1.5x109/L and platelets
             &gt;= 100x109/L), creatinine (GFR&gt;= 60ml/min) and total bilirubin &lt; 1.5 times the upper
             limit of normal; aspartate and alanine aminotransferase &lt; 2,5 times the upper limit of
             normal

          -  All patients will have to sign written informed consent in order to participate in the
             study

        Exclusion Criteria:

          -  Patients with non-squamous tumors who have no contradiction for administration of
             bevacizumab

          -  Active infection or malnutrition (loss of more than 20% of the body weight)

          -  Known hypersensitivity reaction to any of the component of the treatment

          -  Concurrent or previous chronic systemic immune therapy

          -  Pregnancy (absence to be confirmed by ÃŸ-HCG test) or lactation period

          -  Known alcohol/drug abuse

          -  Legal incapacity or limited legal capacity

          -  Medical or psychological condition which in the opinion of the investigator would not
             permit the subject to complete the study or sign meaningful informed consent

          -  A second primary tumor other than non-melanoma skin cancer or in situ cervical
             carcinoma

          -  Previous radiotherapy to the target lesions. Patients treated with palliative
             radiotherapy had to have measurable metastatic disease outside the irradiation fields

          -  Patients with severe cardiac dysfunction, unstable angina petrosis, or high risk of
             uncontrolled arrhythmia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Souglakos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete, Dep of Medical Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University General Hospital of Alexandroupolis, Dept. of Medical Oncology</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Laikon&quot; General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>401 Military Hospital, Medical Oncology Unit</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Air Forces Military Hospital, Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IASO&quot; General Hospital of Athens, 1st Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sotiria&quot; General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Metaxa's&quot; Anticancer Hospital of Piraeus,1st Dep of Medical Oncology</name>
      <address>
        <city>Piraeus</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Theagenion&quot; Anticancer Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2008</study_first_submitted>
  <study_first_submitted_qc>June 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2008</study_first_posted>
  <last_update_submitted>February 12, 2013</last_update_submitted>
  <last_update_submitted_qc>February 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced</keyword>
  <keyword>NSCLC</keyword>
  <keyword>ERCC1</keyword>
  <keyword>RRM1</keyword>
  <keyword>BCRA1</keyword>
  <keyword>Alimta</keyword>
  <keyword>Gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

